MBXMBX Biosciences, Inc.

1. Aug 27, 2026On August 27, 2026, the Company announced the dosing of the first patient in its pivotal Phase 3 oPTimize clinical trial evaluating once-weekly canvuparatide for the treatment of chronic hypoparathyroidism (HP)Regulation FD disclosure · Form 8-K
2. Aug 6, 2026On August 6, 2026, the Company provided an update on its MBX 4291 phase 1 clinical trial. The Company remains on track to report data from the first cohort of the 12-week multiple ascending dose (Part C) in the fourth quarter of 2026.Earnings release · Form 8-K
3. Jul 13, 2026Hawryluk will be stepping away from his role as the Company’s Chief Executive Officer and end his services as a member of the Board effective as of July 13, 2026.Director or officer change · Form 8-K
4. Jun 12, 2026On June 12, 2026, the Company announced one-year data from the Phase 2 Avail™ and OLE clinical trials of canvuparatide in adult patients with chronic HP. The update is summarized below.Regulation FD disclosure · Form 8-K
5. Jun 5, 2026On June 4, 2026, MBX Biosciences, Inc. (the "Company") held its 2026 annual meeting of stockholders (the "Annual Meeting"). As further described under.Director or officer change · Form 8-K
6. May 11, 2026On May 11, 2026, the Company provided an update on its obesity portfolio, including initial data from the MBX 4291 Phase1 clinical trial and nomination of MBX 5765 as its amycretin prodrug development candidate, as well as an update on the imapextide Phase 2a clinical trial.Regulation FD disclosure · Form 8-K
7. May 7, 2026MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights.Earnings release · press release
8. Mar 12, 2026MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights.Earnings release · press release
9. Mar 9, 2026On March 9, 2026, the Company announced completion of an End-of-Phase 2 ("EOP2") meeting with the U.S. Food and Drug Administration ("FDA")Regulation FD disclosure · Form 8-K
10. Feb 27, 2026On February 24, 2026, MBX Biosciences, Inc. (the “Company”) entered into a lease agreement (the “Lease Agreement") with 5 Burlington Woods, LLC ("5 Burlington Woods") to lease approximately 13,642 square feet of new office and laboratory space in Burlington, MA ("the Premises")Material agreement entered · Form 8-K
11. Feb 5, 2026Sales Pursuant to At-the-Market ("ATM") Offering Program On February 4, 2026, MBX Biosciences, Inc. (the “Company”), closed on the sale and issuance of an aggregate of 2,250,986 shares of its common stock (the "Shares") at a volume weighted average price per share of $38.76 for gross proceeds of approximately $87.1 …Other event · Form 8-K
12. Jan 22, 2026Effective as of January 20, 2026, the board of directors (the “Board”) of MBX Biosciences, Inc. (the “Company”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), appointed Laurie Stelzer as a director of the Company.Director or officer change · Form 8-K

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.